(ERF) Eurofins Scientific SE - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: PA (France) | Market Cap: 10.357m EUR | Total Return: 12.1% in 12m
Avg Turnover: 19.4M
EPS Trend: -10.6%
Rev. Trend: 68.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Eurofins Scientific SE (ERF) is a Luxembourg-based global provider of laboratory testing and analytical services. Founded in 1987, the company operates across a diverse range of sectors, including biopharma, clinical diagnostics, food and feed testing, and environmental safety. Its business model relies on a decentralized network of over 900 laboratories, offering specialized technical services such as genomic sequencing, forensic analysis, and regulatory consultancy.
The Testing, Inspection, and Certification (TIC) industry is characterized by high barriers to entry due to stringent regulatory requirements and the need for significant capital investment in specialized equipment. Eurofins utilizes a hub-and-spoke operational strategy, allowing it to scale volume while maintaining local expertise in niche markets like agroscience and material engineering. For a deeper look into the companys fundamental performance metrics, ValueRay provides comprehensive data for further analysis.
The companys service portfolio extends to consumer product testing, sustainability audits, and REACH compliance, positioning it as a critical infrastructure partner for global supply chains. By diversifying its revenue streams across healthcare, industrial, and consumer sectors, Eurofins mitigates cyclical risks associated with specific regional or vertical market fluctuations.
- Growth in biopharma and clinical diagnostics outsourcing fuels long-term revenue expansion
- Post-pandemic testing volume normalization pressures year-over-year organic growth comparisons
- M&A execution and laboratory network integration determine operating margin performance
- Increasing global environmental and food safety regulations drive service demand
- Rising labor costs and inflation impact profitability across labor-intensive lab networks
| Net Income: 881.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 3.69 > 1.0 |
| NWC/Revenue: 1.57% < 20% (prev 7.81%; Δ -6.25% < -1%) |
| CFO/TA 0.23 > 3% & CFO 2.52b > Net Income 881.4m |
| Net Debt (5.08b) to EBITDA (2.49b): 2.04 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (187.0m) vs 12m ago -4.20% < -2% |
| Gross Margin: 41.46% > 18% (prev 0.13%; Δ 4.13k% > 0.5%) |
| Asset Turnover: 130.8% > 50% (prev 91.47%; Δ 39.34% > 0%) |
| Interest Coverage Ratio: 4.24 > 6 (EBITDA TTM 2.49b / Interest Expense TTM 319.1m) |
| A: 0.02 (Total Current Assets 2.65b - Total Current Liabilities 2.43b) / Total Assets 11.0b |
| B: 0.28 (Retained Earnings 3.02b / Total Assets 11.0b) |
| C: 0.12 (EBIT TTM 1.35b / Avg Total Assets 10.9b) |
| D: 0.38 (Book Value of Equity 2.78b / Total Liabilities 7.40b) |
| Altman-Z'' = 2.26 = BBB |
| DSRI: 0.75 (Receivables 1.54b/1.42b, Revenue 14.2b/9.88b) |
| GMI: 0.32 (GM 41.46% / 13.09%) |
| AQI: 0.95 (AQ_t 0.51 / AQ_t-1 0.53) |
| SGI: 1.44 (Revenue 14.2b / 9.88b) |
| TATA: -0.15 (NI 881.4m - CFO 2.52b) / TA 11.0b) |
| Beneish M = -3.71 (Cap -4..+1) = AAA |
As of May 23, 2026, the stock is trading at EUR 62.60 with a total of 207,586 shares traded.
Over the past week, the price has changed by +5.57%,
over one month by +1.09%,
over three months by -4.52% and
over the past year by +12.07%.
Eurofins Scientific SE has no consensus analysts rating.
P/E Trailing = 23.2471
P/E Forward = 14.8148
P/S = 1.4195
P/B = 2.2818
P/EG = 0.9034
Revenue TTM = 14.2b EUR
EBIT TTM = 1.35b EUR
EBITDA TTM = 2.49b EUR
Long Term Debt = 3.71b EUR (from longTermDebt, last quarter)
Short Term Debt = 727.0m EUR (from shortTermDebt, last quarter)
Debt = 5.87b EUR (from shortLongTermDebtTotal, last quarter) + Leases 435.9m
Net Debt = 5.08b EUR (calculated: Debt 5.87b - CCE 791.0m)
Enterprise Value = 15.4b EUR (10.4b + Debt 5.87b - CCE 791.0m)
Interest Coverage Ratio = 4.24 (Ebit TTM 1.35b / Interest Expense TTM 319.1m)
EV/FCF = 12.97x (Enterprise Value 15.4b / FCF TTM 1.19b)
FCF Yield = 7.71% (FCF TTM 1.19b / Enterprise Value 15.4b)
FCF Margin = 8.35% (FCF TTM 1.19b / Revenue TTM 14.2b)
Net Margin = 6.19% (Net Income TTM 881.4m / Revenue TTM 14.2b)
Gross Margin = 41.46% ((Revenue TTM 14.2b - Cost of Revenue TTM 8.34b) / Revenue TTM)
Gross Margin QoQ = 10.45% (prev 22.43%)
Tobins Q-Ratio = 1.40 (Enterprise Value 15.4b / Total Assets 11.0b)
Interest Expense / Debt = 5.44% (Interest Expense 319.1m / Debt 5.87b)
Taxrate = 26.45% (81.4m / 307.8m)
NOPAT = 995.0m (EBIT 1.35b * (1 - 26.45%))
Current Ratio = 1.09 (Total Current Assets 2.65b / Total Current Liabilities 2.43b)
Debt / Equity = 1.66 (Debt 5.87b / totalStockholderEquity, last quarter 3.54b)
Debt / EBITDA = 2.04 (Net Debt 5.08b / EBITDA 2.49b)
Debt / FCF = 4.27 (Net Debt 5.08b / FCF TTM 1.19b)
Total Stockholder Equity = 4.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.09% (Net Income 881.4m / Total Assets 11.0b)
RoE = 18.79% (Net Income TTM 881.4m / Total Stockholder Equity 4.69b)
RoCE = 16.11% (EBIT 1.35b / Capital Employed (Equity 4.69b + L.T.Debt 3.71b))
RoIC = 10.85% (NOPAT 995.0m / Invested Capital 9.17b)
WACC = 5.86% (E(10.4b)/V(16.2b) * Re(6.92%) + D(5.87b)/V(16.2b) * Rd(5.44%) * (1-Tc(0.26)))
Discount Rate = 6.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -84.11 | Cagr: -2.50%
[DCF] Terminal Value 77.97% ; FCFF base≈1.02b ; Y1≈1.17b ; Y5≈1.72b
[DCF] Fair Price = 119.5 (EV 26.0b - Net Debt 5.08b = Equity 20.9b / Shares 174.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -10.59 | EPS CAGR: -1.50% | SUE: N/A | # QB: 0
Revenue Correlation: 68.40 | Revenue CAGR: 9.58% | SUE: -0.01 | # QB: 0
EPS current Year (2026-12-31): EPS=4.01 | Chg30d=+0.20% | Revisions=-40% | GrowthEPS=+3.2% | GrowthRev=+4.1%
EPS next Year (2027-12-31): EPS=4.68 | Chg30d=+0.98% | Revisions=-27% | GrowthEPS=+16.6% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: -40%